Expert Point of View: U.S. Perspective

Get Permission


“The practice of rebiopsy at relapse and metastasis is becoming increasingly common in the United States,” said Hope Rugo, MD, Professor at the University of California, San Francisco.

“More than 20% of patients have differing results from the primary tumor to rebiopsy at disease progression. It could be that diagnostic tests are faulty, but we believe there is some shift in the tumor characteristics as the disease progresses,” she noted.

A good reason to rebiopsy would be disease progression with different characteristics than those from the presentation at primary diagnosis, she continued. Biopsy is not needed in a patient who has a primary tumor and then 15 years later develops bone metastasis, she said. ■

Disclosure: Dr. Rugo reported no potential conflicts of interest.

Related Articles

Changes in Receptor Status during Breast Cancer Progression Warrant Rebiopsies at Relapse

Oncologists should be aware that common clinical tumor markers (denoting hormonal and HER2 status) change as breast cancer progresses, because these changes can affect treatment selection. Estrogen receptor (ER), progesterone receptor (PR), and HER2 receptor status was changed from the time of the...

Expert Point of View: European Perspective

3.2.47_andre.jpgECCO President Michael Baumann, MD, said that the findings on changes in receptor status throughout breast cancer progression were of major importance, “because many patients do not receive optimal treatment for their disease. The price of regular biopsies may seem high, but in the long run they...